Closing the medicine gap

Improving First Nations peoples’ access to medicine
Evohealth acknowledges that we work on the traditional lands of many Aboriginal clans, tribes, and nations.

We commit to working in collaboration with Aboriginal and Torres Strait Islander communities and peoples to improve health, emotional and social well-being outcomes in the spirit of partnership.
About Evohealth

The delivery of healthcare is complex. Our focus is not.

Better health for all Australians.
CLOSING THE MEDICINE GAP: IMPROVING FIRST NATIONS PEOPLES' ACCESS TO MEDICINE
<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>07</td>
<td>Medicine access is essential to the right to health</td>
</tr>
<tr>
<td>08</td>
<td>Facing unique challenges</td>
</tr>
<tr>
<td>10</td>
<td>Current enablers to access</td>
</tr>
<tr>
<td>11</td>
<td>Driving change</td>
</tr>
<tr>
<td>15</td>
<td>Case study: Reacting to an outbreak</td>
</tr>
<tr>
<td>16</td>
<td>Closing the medicine access gap</td>
</tr>
<tr>
<td>18</td>
<td>Abbreviations</td>
</tr>
<tr>
<td>19</td>
<td>References</td>
</tr>
<tr>
<td>21</td>
<td>Disclaimer</td>
</tr>
</tbody>
</table>
Throughout this article we respectfully refer to Aboriginal and Torres Strait Islander peoples as First Nations people. We acknowledge the cultural diversity of First Nations peoples throughout Australia and the hundreds of groups with distinct languages, traditions, and histories.
MEDICINE ACCESS IS ESSENTIAL TO THE RIGHT TO HEALTH

Australia is renowned for its advanced healthcare system, yet it does not serve all Australians equally. First Nations people encounter significant barriers accessing crucial medications and vaccines, resulting in poorer health outcomes and diminished life expectancy. Ensuring that medicines and vaccines are readily available, affordable and clearly understood is vital for maintaining health and preventing illness. [1, 2] Unfortunately, this isn’t always the case for all First Nations people.

This report explores the unique challenges First Nations people face in accessing medicines and vaccines, the efforts currently in place to bridge this gap, and the obstacles that still hinder progress. We also present practical recommendations for enhancing medicine access to ensure equitable health outcomes for all Australians.

The National Medicines Policy: A Framework for Equity

The National Medicines Policy (NMP) serves as a roadmap for ensuring all Australians have equitable access to high-quality medicines and related services. First published in 2000, and extensively reviewed in 2022, the policy is built on four key pillars:

1. Equitable, timely, safe and reliable access to medicines and medicines-related services, at a cost that individuals and the community can afford.
2. Medicines that meet the required standards of quality, safety and efficacy.
3. Quality use of medicines and medicines safety.
4. Collaborative, innovative and sustainable medicines industry and research sectors with the capability, capacity and expertise to respond to current and future health needs.

The NMP specifically recognises the need to address healthcare inequities faced by vulnerable populations, including First Nations Australians It calls for collaboration with Aboriginal and Torres Strait Islander communities to identify priorities and co-create solutions that address their unique healthcare needs and barriers.
FACING UNIQUE CHALLENGES

First Nations people face numerous hurdles in equitably accessing healthcare, including geographic isolation, socioeconomic disadvantage and systemic inequities. These social, cultural and commercial challenges, stem from the lasting effects of colonisation, a healthcare system that doesn’t fully consider their cultural needs, exploitation of their lands, and a range of health determinants. [4,5] These challenges are compounded by a lack of culturally safe healthcare services and appropriate medical information.

First Nations people experience higher rates of chronic disease than other Australians. These conditions, such as diabetes and heart disease, are more common leading to greater burden of illness, disability, and even early death. In fact, chronic diseases account for a staggering 80 per cent of the life expectancy gap between First Nations people and the rest of the population. [6, 7]

Tragically, medicines are readily available in Australia to manage these conditions. Yet, we know that First Nations people are five times more likely to die prematurely from chronic illnesses in our country. [6]

The reported prevalence of type 2 diabetes amongst Aboriginal people in remote communities of the Northern Territory are some of the highest of any population in the world. [8]

The fight against infectious diseases is another challenge for First Nations Australians. While some illnesses, like Acute Rheumatic Fever (ARF) and Rheumatic Heart Disease (RHD) that can occur following a Streptococcus infection have become less common in Australia thanks to antibiotics and better living conditions, progress has not reached First Nations communities as effectively. Australia holds the dubious honour of having some of the highest rates of RHD in the world, despite being a disease entirely preventable with access to medicine. [9]
In the Northern Territory, 92 per cent of people with Rheumatic Heart Disease are Indigenous. [10]

DELIVERING CARE

Delivering healthcare in remote areas comes with its own set of challenges. While First Nations people make up only 1.8 per cent of those living in major cities, they comprise 32 per cent of the population in Australia’s most remote areas. [11, 12] Providing culturally sensitive care in these locations falls to a mix of organisations: Aboriginal Community Controlled Health Organisations (ACCHOs), state/territory or local health services, or non-government organisations. [6]

Attracting and retaining qualified healthcare workers in these remote regions is challenging, specialty care is rare and patients can be hours away from the nearest healthcare facility. In fact, only one per cent of General Practitioners (GPs) would consider working in the most remote areas of Australia. [13]

Adding to this complexity is that essential medicines are not always available at the local pharmacy, or Aboriginal Health Service (AHS). We also know that First Nations people seek and access significantly fewer medicines compared to other Australians. In fact, they spend hundreds of dollars less per person on essential medications (Figure 1).

*Figure 1: Expenditure on mainstream PBS and RPBS per person, by Indigenous status, 2010–11 to 2016–17*

These unique and difficult challenges faced by First Nations people contribute to inequity of care and access. This, in turn, fuels poorer health outcomes and life expectancy, which has become far too normalised. To ensure everyone has a fair chance at a long and healthy life, this gap needs to be addressed.
Despite these challenges, successive governments have sought to address this gap. Several government-funded programs are making strides in improving access to medicines for First Nations people:

1. **Closing the Gap (CTG) Pharmaceutical Benefits Scheme (PBS) Co-payment Program:**
   This program reduces the cost of PBS medicines for First Nations people, making essential medicines more affordable. [14]

2. **Indigenous Health Services Pharmacy Support (IHSPS) Program:**
   This initiative funds Aboriginal Community Controlled Health Organisations (ACCHOs) to enhance quality use of medicines through pharmacist support, educational activities, and patient transport. [15]

3. **Remote Area Aboriginal Health Services (RAAHS) Program:**
   Enables remote Aboriginal health services to provide PBS-listed medicines at no cost. [16]

4. **Indigenous Dose Administration Aids (IDAA) Program:**
   Provides special packaging for medicines to help patients manage their treatment schedules. [17]

5. **Integrating Pharmacists within ACCHOs (IPAC):**
   Embeds pharmacists in ACCHOs to improve chronic disease management, with promising outcomes leading to public funding recommendations.
In our research we have identified, four key opportunities that can substantially improve health outcomes of First Nations people. These will enhance cultural safety, reduce administrative hurdles, decrease the cost and improve availability of medicines and vaccines.

1. CREATE CULTURALLY SAFE CARE

In a thriving healthcare system, everyone should feel welcome and understood. In Australia, there are barriers to accessing healthcare and, in turn, worse health outcomes, amongst a number of culturally and linguistically diverse groups. [18] For First Nations people, cultural safety is key to unlocking better health outcomes.

Aboriginal and Torres Strait Islander Health Workers (ATSIHWs) play a vital role in providing specialised healthcare, increasing cultural safety, and improving health outcomes for First Nations people. This culturally appropriate care builds trust and incorporates traditional knowledge to deliver the best possible care.

Currently ATSIHW’s skills and importance are not reflected in their rights as health professionals. Including prescribing. Despite often having the best opportunity for intervention and point of care provision of medicines, the restrictions on prescribing mean opportunities for improved access to medicines are missed.

When it comes to pharmacist access, the IPAC program demonstrated better health outcomes for patients with chronic disease, following 26 pharmacists working within ACCHOs across the Northern Territory, Queensland and Victoria. In 2023, the Australian Government’s Medical Services Advisory Committee (MSAC) recommended that the IPAC model be publicly funded. Acting on this recommendation will support further access to culturally safe care for First Nations people. [19]

2. ACTIVELY IDENTIFY APPROPRIATE MEDICINES AND VACCINES

The current system for recommending new medicines often overlooks the specific needs of First Nations people. In Australia, the Pharmaceutical Benefits Advisory Committee (PBAC) recommends which drugs should be listed on and subsidised under the PBS, while two subcommittees consider projected use and cost of medicines, and the clinical and economic evaluations of submissions. [21, 22]
Currently, applications for listing of new drugs are led by pharmaceutical companies under a cost recovery process, involving fees at each stage. The fees range from $33,370 to $400,000 for a full Category 1 submission recommended by the PBAC at its first submission.

These costs are prohibitive for non-pharmaceutical organisations. Fee waivers can be granted for a number of reasons, including if the submission is of public interest and used “for medical treatment of Aboriginal and Torres Strait Islander peoples”. [24] There have already been instances where Aboriginal and Torres Strait Islander groups, in association with the pharmaceutical industry, have actively identified essential medications for First Nations communities. For example, NACCHO led a submission to expand the listing of Prednefrin Forte to provide post-cataract surgical access for Aboriginal and Torres Strait Islander people. [25] Similarly, an outbreak of syphilis in recent years amongst younger First Nations people led to a rapid and coordinated response by Government and other stakeholders, leading to ready access to appropriate treatment (see page 15).

There are only 25 medicines listed on the PBS specifically for First Nations people. [23]

Future collaborations with peak bodies leading the charge, will help ensure everyone has access to the life-saving medicines they deserve.

**Health Technology Assessment and Policy Review**

The Australian Government has recently released an options paper on Health Technology Assessment (HTA), as part of the Health Technology Assessment and Policy Review. [26] It outlined the process of how medicines and vaccines are listed on the PBS, acknowledging a critical problem due to the lack of formal and regular involvement of First Nations people in the process. This exclusion has resulted in health inequity, with essential medicines often not listed on the PBS for First Nations communities.

The paper proposed a range of options to improve equitable access to life-saving medicines and vaccines for all Australians, including First Nations people. These proposals include:

- establishing a First Nations Advisory Committee;
- creating First Nations representation on the PBAC;
- dedicating resources to assist organisations representing First Nations health for HTA applications;
- developing a priority list in collaboration with ACCHOs to identify essential medicines and therapies; and
- creation of a framework for considering equity in HTA decision-making.

At the time of this report’s publication, the Government had yet to announce a response to the paper.
3. IMPROVE HOW MEDICINES AND VACCINES ARE ACCESSED

Several opportunities exist to improve how medicines and vaccines are accessed, including the place of care and leveraging long-standing PBS programs, particularly the Prescriber Bag.

**Place of care**

For many First Nations people, ACCHOs are a safe haven. However, the inability of many of these health settings to dispense and provide ready access to medicines creates an unnecessary hurdle.

The RAAHS program acknowledges that accessible pharmacies and medical services may be scarce in remote Australia. It also recognises that obtaining prescriptions or traveling long distances to obtain them can be a barrier. Providing some amelioration of this problem are that more than 160 AHS are utilising the RAAHS program. These provide a vital service in remote communities as a source of approved essential medicines. Programs like RAAHS are a step in the right direction, allowing approved ACCHOs to directly provide essential medicines. Expanding access would eliminate many barriers and ensure patients receive the treatment at the point of care.

**PBS Prescriber Bag**

For First Nations communities, remote locations and limited access to pharmacies can also create significant hurdles in obtaining emergency medical care. The Prescriber Bag program helps bridge this gap by providing medical and nurse practitioners with essential medications they can dispense directly to patients in urgent situations. [28] This program ensures First Nations people have immediate access to critical medications, potentially saving lives and improving health outcomes.

The Prescriber Bag medicines and vaccines are carefully selected based on the specific needs of the community and the types of emergencies likely to be encountered. [29] This ensures healthcare providers have the necessary medicines to deliver timely and effective care, even in remote areas. Further development of this program could enhance access for First Nations people.
Reducing the cost of PBS medicines and vaccines through the CTG PBS co-payment program is an important program, the integrity of which must be maintained by future governments. Removal of some non-prescription medicines in the past has disrupted access.

Changing medicines from prescription to over the counter (OTC) is often seen as enabling access to medicines. However, for First Nations people who may be eligible for PBS listed drugs at concessional prices or without cost, down scheduling to OTC and resulting removal from the PBS can introduce a financial barrier.

For example, the down scheduling of chloramphenicol eye products. This product treats eye infections, which are three times higher amongst First Nations people than non-Indigenous Australians. [6] From 2016 it was removed from the PBS and patients were required to pay full non-subsidised price. It was soon realised, however, that this change had introduced a potential barrier to access for First Nations people. As a result, in 2017, chloramphenicol eye products returned to the PBS under the CTG program for patients identifying as Aboriginal and Torres Strait Islander people. As this example highlights, the risks associated with increased patient costs when essential medications are moved off the PBS list should be borne in mind and avoided or mitigated so as not to undermine health objectives.

The integrity of the Closing the Gap PBS co-payment program must be maintained by future Governments.
In recent years an outbreak of syphilis spread rapidly, particularly among young First Nations people, in parts of Australia. [30] The Australian government, working with NACCHO and Flinders University, mounted a focussed response to reduce the problem. Part of this response included point of care testing and a “test and treat” model. Additionally, in 2019 an effective treatment, benzathine benzylpenicillin was added to the PBS Prescribers Bag for Aboriginal and Torres Strait Islander patients in non-remote areas. [31, 32] This meant patients could receive ‘on the spot’, urgent treatment following testing without any financial cost.

This addition, led to a steady increase in the prescribing of benzathine benzylpenicillin for this purpose (see figure 2). Fewer supplies were made in 2019, as listed occurred in September. [33]

NACCHO collaborated with ACCHO member services, clinicians, and the Royal Australian College of General Practitioners (RACGP) to write a submission to the PBAC for this important listing. [32] While the PBAC process can be complex and expensive, this example highlights the power of needs-driven submissions in ensuring access to essential medications.
CLOSING THE MEDICINE ACCESS GAP

To bridge the gap in medicine access for First Nations people, we propose the following recommendations:

**RECOMMENDATION 1**

Amplify First Nations voice in the PBAC process

Giving First Nations people the opportunity to advise on health matters that impact them will contribute to better care. Following the proposal in the HTA Review Options paper, establishing an additional subcommittee comprised of First Nations patients and representatives from Aboriginal health services, the PBAC will gain invaluable insights into the specific needs and barriers faced by these communities. This will ensure decisions regarding medicine access are reviewed by those who will be most affected.

**RECOMMENDATION 2**

Embed culturally safe care in ACCHOs

We know that empowering First Nations people to take control of their health is essential for improving health outcomes. Expanding the IPAC program by embedding pharmacists within ACCHOs would enhance cultural safe care within these services. Broadening the prescribing rights of ATSIHWs would also provide greater accessibility and culturally sensitive care.

**RECOMMENDATION 3**

Unlock access through PBAC fee waivers

The current system for submitting applications to the PBAC can be a financial hurdle for non-industry groups. To address this, we propose automatic fee waivers for any application related to Aboriginal and Torres Strait Islander health. Additionally, government-provided assistance with writing these submissions would empower these communities to advocate for their specific health needs. These measures, while not eliminating the role of industry, would open the door for more community co-led applications, ensuring the PBAC considers a wider range of needs-driven medicines for First Nations Australians.
RECOMMENDATION 4

Expand the PBS Prescribers Bag

The successful addition of benzathine benzylpenicillin for treating syphilis to the Prescribers Bag program exemplifies the power of active measures. Further expanding this program would equip ACCHOs to hold and dispense PBS-funded medications directly to their patients. This eliminates the need for ACCHOs to purchase and stock medicines at their own expense, a significant financial burden for many services.

Achieving equitable access to medicines for First Nations people is a complex undertaking, but necessary endeavour. By building on existing initiatives and implementing these targeted recommendations, we can do much to bridge the gap and ensure a healthier future for all Australians.

Equitable access to medicines is a fundamental right and a crucial component of achieving health equality. By addressing the unique challenges faced by First Nations people and enhancing existing programs, we can make significant strides towards closing the health gap. At Evohealth, we are dedicated to advocating for and implementing solutions that promote better health for all.
# Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACCHOs</td>
<td>Aboriginal Community Controlled Health Organisations</td>
</tr>
<tr>
<td>AHS</td>
<td>Aboriginal Health Service</td>
</tr>
<tr>
<td>AIHW</td>
<td>Australian Institute of Health and Welfare</td>
</tr>
<tr>
<td>ARF</td>
<td>Acute Rheumatic Fever</td>
</tr>
<tr>
<td>ATSIHW</td>
<td>Aboriginal and Torres Strait Islander Health Workers</td>
</tr>
<tr>
<td>CTG</td>
<td>Closing the Gap</td>
</tr>
<tr>
<td>GP</td>
<td>General Practitioner</td>
</tr>
<tr>
<td>HTA</td>
<td>Health Technology Assessment</td>
</tr>
<tr>
<td>IDAA</td>
<td>Indigenous Dose Administration Aids</td>
</tr>
<tr>
<td>IHSPS</td>
<td>Indigenous Health Services Pharmacy Support</td>
</tr>
<tr>
<td>IPAC</td>
<td>Indigenous Pharmacy Assistance Scheme</td>
</tr>
<tr>
<td>MBS</td>
<td>Medicare Benefits Schedule</td>
</tr>
<tr>
<td>MSAC</td>
<td>Medical Services Advisory Committee</td>
</tr>
<tr>
<td>NMP</td>
<td>National Medicines Policy</td>
</tr>
<tr>
<td>OTC</td>
<td>Over the counter</td>
</tr>
<tr>
<td>PBAC</td>
<td>Pharmaceutical Benefits Advisory Committee</td>
</tr>
<tr>
<td>PBS</td>
<td>Pharmaceutical Benefits Scheme</td>
</tr>
<tr>
<td>RAAHS</td>
<td>Remote Area Aboriginal Health Services</td>
</tr>
<tr>
<td>RACGP</td>
<td>Royal Australian College of General Practitioners</td>
</tr>
<tr>
<td>RHD</td>
<td>Rheumatic Heart Disease</td>
</tr>
</tbody>
</table>
REFERENCES


33. Cleary, P. In good hands: the people and communities behind Aboriginal-led solutions. 2019; Oxfam Australia.

This Report has been prepared by Evohealth Pty Ltd (Evohealth).

This Report is not intended to be and should not be used by any other person or entity other than a Recipient and Evohealth accepts no duty of care whatsoever to any such other person or entity.

While reasonable efforts have been made to ensure that the contents of this Report are factually correct, this Report is provided by Evohealth on a general basis only. Neither Evohealth or any of its directors, officers, employees, advisers, consultants, contractors, and agents make any representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of the information referred to or contained in this Report and none of those persons or entities accepts any responsibility or liability (except a liability that cannot lawfully be excluded) for any reliance placed on the contents of this Report by any person. This Report does not purport to be comprehensive or to contain all the information a Recipient may desire or require in respect of its subject matter. The Recipient should make its own enquiries and obtain its own independent advice in relation to the information contained within this Report before making any decision or taking any action based on its contents.

To the maximum extent permitted by law, Evohealth and its directors, officers, employees, advisers, consultants, contractors and agents disclaim and exclude all liability for any loss, claim, demand, damages, costs and expenses of whatsoever nature (whether or not foreseeable): suffered or incurred by any person relying or acting on any information provided in, or omitted from, this Report or any other written or oral opinions, advice or information provided by any of them; or arising as a result of or in connection with information in this Report being inaccurate or incomplete in any way or by reason of any reliance thereon by any person; and whether caused by reason of any negligence, accident, default or however otherwise caused.

Each recipient of this report acknowledges and accepts each of the matters and conditions contained in this Disclaimer.

Date of preparation: May 2024.

Authors: Renae Beardmore, and Isabella Marovich.

Report design: Adam Sorgini

Photo Credits: Cover Photo by Amanda Thorson
Page 13 image by Rene Riegal (Unsplash)
